Literature DB >> 10415931

Novel targets and techniques in imidazoline receptor research.

I F Musgrave1, R A Hughes.   

Abstract

Imidazoline binding sites are now generally accepted as being receptors. Despite this acceptance, the molecular structure and signal transduction mechanisms of these receptors are still poorly understood. The I1-imidazoline binding site (I1-receptor) is localized to the plasma membrane, but it is not clear if this represents a conventional receptor. It is also not clear if there are multiple forms of the I1-receptor. The signal transduction mechanisms of I1-receptors are similarly unclear, but much progress has been made. Evidence clearly indicates that ligands with high affinity for I1-receptors stimulate a novel signal transduction pathway, phosphatidylcholine-selective phospholipase C, in the rat adrenal medullary tumor cell line PC-12. However, this may not be the case in all cell types as microphysiometry, a novel technique for determining cellular activation, could not detect receptor activation in cultured bovine adrenal medullary cells exposed to a number of imidazolines considered to be agonists at the I1-receptor. This suggests that there is no I1-receptor-mediated stimulation of phosphatidylcholine-specific phospholipase C in these cells. By contrast, nicotine-stimulated increases in ion entry were blocked by clonidine. Ion channels have been suggested as another possible I1-imidazoline "receptor" family and may represent the low affinity I1-receptor. I1-Receptor ligands can be shown to bind to, or block, the following members of the ligand-gated ion channel super family, the 5HT3, K+ATP, NMDA, and nicotinic acetylcholine receptors. The site of action appears to be the phencyclidine binding site in these channels, but other possibilities cannot be excluded. Molecular modeling suggests that I1-receptor-selective ligands share a common three-dimensional structure with phencyclidine, providing a basis for these actions. This suggests that a phencyclidine-binding site motif may represent a novel site of action for I1-receptor ligands and that searches for receptors based on this motif may reveal novel imidazoline "receptors."

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415931     DOI: 10.1111/j.1749-6632.1999.tb09375.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Electrophilically activated nitroalkanes in reaction with aliphatic diamines en route to imidazolines.

Authors:  Alexander V Aksenov; Nicolai A Aksenov; Nikolai A Arutiunov; Vladimir V Malyuga; Sergey N Ovcharov; Michael Rubin
Journal:  RSC Adv       Date:  2019-11-29       Impact factor: 4.036

2.  I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Authors:  Yaron D Barac; Orit Bar-Am; Esti Liani; Tamar Amit; Luba Frolov; Elena Ovcharenko; Itzchak Angel; Moussa B H Youdim; Ofer Binah
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

3.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.